The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma

被引：32

作者：

Brar, Gagandeep ^{[2
]}

Shah, Manish A. ^{[1
]}

机构：

[1] Weill Cornell Med New York Presbyterian Hosp, Div Hematol & Med Oncol, 1305 York Ave,Room Y1247, New York, NY 10021 USA

[2] NCI, Thorac & GI Malignancies Branch, Ctr Canc Res, Bethesda, MD 20892 USA

来源：

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY | 2019年 / 12卷

关键词：

checkpoint blockade; gastric cancer; immunotherapy; RANDOMIZED PHASE-III; LIGAND; EXPRESSION; CLINICAL-SIGNIFICANCE; IMMUNOHISTOCHEMISTRY ASSAY; 2ND-LINE THERAPY; DOUBLE-BLIND; CANCER; CHEMOTHERAPY; FLUOROURACIL; CISPLATIN;

D O I：

10.1177/1756284819869767

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Gastric cancer is a leading cause of cancer-related death worldwide. Recent evidence suggests that gastric cancer is a complex and heterogenous disease with emerging subtypes shown to affect response to treatment and survival. Immunotherapy is an advancing field and immune checkpoint inhibitors have become standard treatment options in numerous tumor types. In this review, we discuss the current and evolving use of checkpoint blockade, focusing on the anti-PD-1 inhibitor, pembrolizumab, for use in advanced gastric and gastroesophageal cancers.

引用

页数：12

共 66 条

[61] B7-H1 glycoprotein blockade: A novel strategy to enhance immunotherapy in patients with renal cell carcinoma [J].

Thompson, RH ;

Webster, WS ;

Cheville, JC ;

Lohse, CM ;

Dong, HD ;

Leibovich, BC ;

Kuntz, SM ;

Sengupta, S ;

Kwon, ED ;

Blute, ML .

UROLOGY, 2005, 66 (5A) :10-14

[62]

US Food and Drug Administration, 2017, FDA grants accelerated approval to avelumab for urothelial carcinoma

[63] Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study [J].

Van Cutsem, E. ;

Boni, C. ;

Tabernero, J. ;

Massuti, B. ;

Middleton, G. ;

Dane, F. ;

Reichardt, P. ;

Pimentel, F. L. ;

Cohn, A. ;

Follana, P. ;

Clemens, M. ;

Zaniboni, A. ;

Moiseyenko, V. ;

Harrison, M. ;

Richards, D. A. ;

Prenen, H. ;

Pernot, S. ;

Ecstein-Fraisse, E. ;

Hitier, S. ;

Rougier, P. .

ANNALS OF ONCOLOGY, 2015, 26 (01) :149-156

[64] The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis [J].

Wang, A. ;

Wang, H. Y. ;

Liu, Y. ;

Zhao, M. C. ;

Zhang, H. J. ;

Lu, Z. Y. ;

Fang, Y. C. ;

Chen, X. F. ;

Liu, G. T. .

EJSO, 2015, 41 (04) :450-456

[65] Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial [J].

Wilke, Hansjochen ;

Muro, Kei ;

Van Cutsem, Eric ;

Oh, Sang-Cheul ;

Bodoky, Gyoergy ;

Shimada, Yasuhiro ;

Hironaka, Shuichi ;

Sugimoto, Naotoshi ;

Lipatov, Oleg ;

Kim, Tae-You ;

Cunningham, David ;

Rougier, Philippe ;

Komatsu, Yoshito ;

Ajani, Jaffer ;

Emig, Michael ;

Carlesi, Roberto ;

Ferry, David ;

Chandrawansa, Kumari ;

Schwartz, Jonathan D. ;

Ohtsu, Atsushi .

LANCET ONCOLOGY, 2014, 15 (11) :1224-1235

[66] Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial [J].

Zhu, Andrew X. ;

Finn, Richard S. ;

Edeline, Julien ;

Cattan, Stephane ;

Ogasawara, Sadahisa ;

Palmer, Daniel ;

Verslype, Chris ;

Zagonel, Vittorina ;

Fartoux, Laetitia ;

Vogel, Arndt ;

Sarker, Debashis ;

Verset, Gontran ;

Chan, Stephen L. ;

Knox, Jennifer ;

Daniele, Bruno ;

Webber, Andrea L. ;

Ebbinghaus, Scot W. ;

Ma, Junshui ;

Siegel, Abby B. ;

Cheng, Ann-Lii ;

Kudo, Masatoshi .

LANCET ONCOLOGY, 2018, 19 (07) :940-952

← 1 2 3 4 5 6 7 →